Mouton Jomien M, Pellizzon Adriano S, Goosen Althea, Kinnear Craig J, Herbst Philip G, Brink Paul A, Moolman-Smook Johanna C
SA MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town South Africa.
Cardiovasc J Afr. 2015 Mar-Apr;26(2):63-9. doi: 10.5830/CVJA-2015-019.
The minimum criterion for the diagnosis of hypertrophic cardiomyopathy (HCM) is thickening of the left ventricular wall, typically in an asymmetrical or focal fashion, and it requires no functional deficit. Using this criterion, we identified a family with four affected individuals and a single unrelated individual essentially with restrictive cardiomyopathy (RCM). Mutations in genes coding for the thin filaments of cardiac muscle have been described in RCM and HCM with 'restrictive features'. One such gene encodes for cardiac troponin I (TNNI3), a sub-unit of the troponin complex involved in the regulation of striated muscle contraction. We hypothesised that mutations in TNNI3 could underlie this particular phenotype, and we therefore screened TNNI3 for mutations in 115 HCM probands.
Clinical investigation involved examination, echocardiography, chest X-ray and an electrocardiogram of both the index cases and close relatives. The study cohort consisted of 113 South African HCM probands, with and without known founder HCM mutations, and 100 ethnically matched control individuals. Mutation screening of TNNI3 for diseasecausing mutations were performed using high-resolution melt (HRM) analysis.
HRM analyses identified three previously described HCM-causing mutations (p.Pro82Ser, p.Arg162Gln, p.Arg170Gln) and a novel exonic variant (p.Leu144His). A previous study involving the same amino acid identified a p.Leu144Gln mutation in a patient presenting with RCM, with clinical features of HCM. We observed the novel p.Leu144His mutation in three siblings with clinical RCM and varying degrees of ventricular hypertrophy. The isolated index case with the de novo p.Arg170Gln mutation presented with a similar phenotype. Both mutations were absent in a healthy control group.
We have identified a novel disease-causing p.Leu144His mutation and a de novo p.Arg170Gln mutation associated with RCM and focal ventricular hypertrophy, often below the typical diagnostic threshold for HCM. Our study provides information regarding TNNI3 mutations underlying RCM in contrast to other causes of a similar presentation, such as constrictive pericarditis or infiltration of cardiac muscle, all with marked right-sided cardiac manifestations. This study therefore highlights the need for extensive mutation screening of genes encoding for sarcomeric proteins, such as TNNI3 to identify the underlying cause of this particular phenotype.
肥厚型心肌病(HCM)诊断的最低标准是左心室壁增厚,通常呈不对称或局灶性增厚,且无需存在功能缺陷。依据这一标准,我们鉴定出一个有四名患病个体的家系以及一名基本患有限制型心肌病(RCM)的无关个体。在RCM以及具有“限制型特征”的HCM中,已发现编码心肌细肌丝的基因突变。其中一个这样的基因编码心肌肌钙蛋白I(TNNI3),它是参与调节横纹肌收缩的肌钙蛋白复合物的一个亚基。我们推测TNNI3突变可能是这种特殊表型的基础,因此我们在115名HCM先证者中筛查了TNNI3的突变情况。
临床调查包括对索引病例及其近亲进行体格检查、超声心动图检查、胸部X线检查和心电图检查。研究队列由113名南非HCM先证者组成,其中有无已知的奠基者HCM突变,以及100名种族匹配的对照个体。使用高分辨率熔解(HRM)分析对TNNI3进行致病突变的筛查。
HRM分析鉴定出三个先前描述的导致HCM的突变(p.Pro82Ser、p.Arg162Gln、p.Arg170Gln)以及一个新的外显子变异(p.Leu144His)。一项涉及相同氨基酸的先前研究在一名表现为RCM且具有HCM临床特征的患者中鉴定出p.Leu144Gln突变。我们在三名患有临床RCM且伴有不同程度心室肥厚的同胞中观察到了新的p.Leu144His突变。携带新发p.Arg170Gln突变的孤立索引病例表现出相似的表型。这两种突变在健康对照组中均不存在。
我们鉴定出一个新的致病p.Leu144His突变以及一个与RCM和局灶性心室肥厚相关的新发p.Arg170Gln突变,后者通常低于HCM的典型诊断阈值。我们的研究提供了关于RCM潜在的TNNI3突变的信息,与类似表现的其他病因,如缩窄性心包炎或心肌浸润等形成对比,这些病因均伴有明显的右心表现。因此,本研究强调了对编码肌节蛋白的基因,如TNNI3进行广泛突变筛查以确定这种特殊表型潜在病因的必要性。